Circulating Tumor Cell Levels and Carcinoembryonic Antigen: An Improved Diagnostic Method for Lung Adenocarcinoma

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2018 Sep 5

PMID 30178907

Citations 13

Authors

Cheng Ding

Xiaofei Zhou

Chun Xu

Jun Chen

Shen Ju

Tengfei Chen

Zhipan Liang

Zihan Cui

Chang Li

Jun Zhao

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to determine a correlation between benign and malignant lung solitary pulmonary nodules (SPN), and analyze the association between circulating tumor cell (CTC) levels and different subtypes of lung adenocarcinoma.

Methods: A total of 200 patients (80 with SPNs and 120 diagnosed with lung cancer) were included in the study. The CTC levels were quantified by identifying the folate receptor on the surface of tumor cells; clinical tumor specific markers were detected by biochemical immunization. The content of peripheral blood CTCs in benign and malignant lung SPN patients was detected and the differences in preoperative CTC levels in different pathological subtypes were analyzed. Based on the collected data, receiver operating characteristic curves were calculated and the rate of lung cancer was predicted.

Results: The peripheral blood CTC levels in patients with malignant lung SPNs were higher than in patients with benign SPNs. The maximum nodule diameter, carcinoembryonic antigen, and CTC levels were independent risk factors for malignant lung SPNs. The peripheral blood CTC levels in patients with stage III-IV lung adenocarcinoma were higher than in stage I-II patients. The peripheral blood CTC levels in patients with microinvasive and invasive adenocarcinoma were higher than in adenocarcinoma in situ patients. The CTC levels in the peripheral blood of patients with maximum tumor diameter > 2 cm were higher than in patients with tumors < 2 cm.

Conclusion: The detection of CTCs can be used as a biomarker for screening SPNs and diagnosing early-stage lung cancer. Using the combination of CTC levels and CEA significantly improves the efficacy of lung adenocarcinoma diagnosis.

Citing Articles

Serum lncRNA THRIL predicts benign and malignant pulmonary nodules and promotes the progression of pulmonary malignancies.

Chen X, Zhu X, Yan W, Wang L, Xue D, Zhu S BMC Cancer. 2023; 23(1):755.

PMID: 37582734 PMC: 10426220. DOI: 10.1186/s12885-023-11264-9.

Preoperative levels of folate receptor-positive circulating tumor cells in different subtypes of early-stage lung adenocarcinoma: Predictive value for determining extent of surgical resection.

Zhou C, Zhao R, Zhao R, Wang A, Li W Front Oncol. 2023; 13:1119807.

PMID: 37139152 PMC: 10150082. DOI: 10.3389/fonc.2023.1119807.

The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.

Xu Y, Li Q, Lin Z, Lin Y Clin Respir J. 2023; 17(5):374-383.

PMID: 36977421 PMC: 10214578. DOI: 10.1111/crj.13601.

Value of peripheral blood circulating tumor cell detection in the diagnosis of thoracic diseases and the prediction of severity.

Qi C, Xiong X Clin Exp Med. 2023; 23(6):2331-2339.

PMID: 36929453 PMC: 10543157. DOI: 10.1007/s10238-023-01022-3.

Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges?.

Voigt W, Prosch H, Silva M Cancers (Basel). 2023; 15(4).

PMID: 36831559 PMC: 9954060. DOI: 10.3390/cancers15041218.

References

Qi F, Liu Y, Zhao R, Zou X, Zhang L, Li J . Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance. Tumour Biol. 2014; 35(7):7217-23. DOI: 10.1007/s13277-014-1894-0. View

Lin M, Chen J, Lu Y, Zhang Y, Song J, Hou S . Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res. 2014; 47(10):2941-50. PMC: 4204926. DOI: 10.1021/ar5001617. View

Ge M, Shi D, Wu Q, Wang M, Li L . Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol. 2005; 132(4):248-56. DOI: 10.1007/s00432-005-0059-3. View

Chen W, Li H, Sun K, Zheng R, Zhang S, Zeng H . [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018; 40(1):5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002. View

Lou J, Ben S, Yang G, Liang X, Wang X, Ni S . Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One. 2013; 8(12):e80458. PMC: 3855610. DOI: 10.1371/journal.pone.0080458. View

Divisi D, Barone M, Bertolaccini L, Rocco G, Solli P, Crisci R . Standardized uptake value and radiological density attenuation as predictive and prognostic factors in patients with solitary pulmonary nodules: our experience on 1,592 patients. J Thorac Dis. 2017; 9(8):2551-2559. PMC: 5594188. DOI: 10.21037/jtd.2017.06.124. View

Torre L, Siegel R, Islami F, Bray F, Jemal A . Worldwide Burden of and Trends in Mortality From Gallbladder and Other Biliary Tract Cancers. Clin Gastroenterol Hepatol. 2017; 16(3):427-437. DOI: 10.1016/j.cgh.2017.08.017. View

Shimada R, Iinuma H, Akahane T, Horiuchi A, Watanabe T . Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol Rep. 2012; 27(4):947-53. PMC: 3583432. DOI: 10.3892/or.2012.1649. View

Paget S . The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989; 8(2):98-101. View

10.

Stieber P, Dienemann H, Schalhorn A, Schmitt U, Reinmiedl J, Hofmann K . Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. Anticancer Res. 1999; 19(4A):2673-8. View

11.

Nunez M, Behrens C, Woods D, Lin H, Suraokar M, Kadara H . High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012; 7(5):833-40. PMC: 3383601. DOI: 10.1097/JTO.0b013e31824de09c. View

12.

Parker N, Turk M, Westrick E, Lewis J, Low P, Leamon C . Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005; 338(2):284-93. DOI: 10.1016/j.ab.2004.12.026. View

13.

Wang L, Wu C, Qiao L, Yu W, Guo Q, Zhao M . Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer. J Cancer. 2017; 8(1):104-110. PMC: 5264045. DOI: 10.7150/jca.16856. View

14.

Detterbeck F, Boffa D, Tanoue L . The new lung cancer staging system. Chest. 2009; 136(1):260-271. DOI: 10.1378/chest.08-0978. View

15.

Joosse S, Pantel K . Biologic challenges in the detection of circulating tumor cells. Cancer Res. 2012; 73(1):8-11. DOI: 10.1158/0008-5472.CAN-12-3422. View

16.

Hofman V, Ilie M, Long E, Selva E, Bonnetaud C, Molina T . Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2010; 129(7):1651-60. DOI: 10.1002/ijc.25819. View

17.

Lian H, Ding Z, Yuan D, Ma J, Qin J . [Diagnostic Value of Folate Receptor-positive Circulating Tumor Cell in Lung Cancer: A Pilot Study]. Zhongguo Fei Ai Za Zhi. 2016; 19(12):813-820. PMC: 5973455. DOI: 10.3779/j.issn.1009-3419.2016.12.03. View

18.

Hu B, Rochefort H, Goldkorn A . Circulating tumor cells in prostate cancer. Cancers (Basel). 2013; 5(4):1676-90. PMC: 3875960. DOI: 10.3390/cancers5041676. View

19.

Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy R, Azizi E . Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014; 5(23):12383-97. PMC: 4323004. DOI: 10.18632/oncotarget.2592. View

20.

Crosbie P, Shah R, Summers Y, Dive C, Blackhall F . Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Transl Lung Cancer Res. 2015; 2(5):382-97. PMC: 4367728. DOI: 10.3978/j.issn.2218-6751.2013.09.02. View